Abstract
Molecular radiotherapy combines the potential of a specific tracer (vector) targeting tumor cells with local radiotoxicity. Designing a specific tumor-targeting/killing combination is a tailoring process. Radionuclides with imaging capacity serve best in the selection of the targeting molecule. The potential of targeted therapy with radiolabeled peptides has been reported in many conditions; peptide receptor radionuclide therapy (PRRT) is already part of Scandinavian guidelines for treating neuroendocrine tumors. Lu-177- and Y-90-labeled somatostatin analogs, including DOTATOC, DOTANOC, and DOTATATE, are most the commonly used and have turned out to be effective. For routine use, an efficient, rapid, and reliable dose calculation tool is needed. In this chapter we describe how serial pre- and posttherapeutic scans can be used for dose calculation and for predicting therapy doses. Our software for radionuclide dose calculation is a three-dimensional, voxel-based system. The 3D dose calculation requires coregistered SPECT image sets from several time points after infusion to reconstruct time-activity curves for each voxel. Image registration is done directly by SPECT image registration using the first time point as a target. From the time-activity curves, initial activity and total half-life maps are calculated to produce a cumulated activity map. The cumulated activity map is then convoluted with a voxel-dose kernel to obtain a 3D dose map. We performed dose calculations similarly for both therapeutic and preplanning images. Preplanning dose was extrapolated to predict therapy dose using the ratio of administered activities. Our 3D dose calculation results are also compared with those of OLINDA. Our preliminary results indicate that dose planning using pretherapeutic scanning can predict critical organ and tumor doses. In some cases, the dose planning prediction resulted in slight, and slightly dose-dependent, overestimation of final therapy dose. Real tumor dose was similar in both pretherapeutic and posttherapeutic scans using our software. The OLINDA software and our program gave similar normal organ doses, whereas tumor doses could be calculated in a more detailed manner using the 3D program.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bakker WH, Breeman WA, Kwekkeboom DJ et al (2006) Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate. Q J Nucl Med Mol Imaging 50:265–271
Bodei L, Cremonesi M, Ferrari M et al (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35:1847–1856
Bodei L, Cremonesi M, Grana CM et al (2011) Peptide receptor radionuclide therapy with (177)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 38(12):2125–2135 epub Sept 3
Cremonesi M, Ferrari M, Bodei L et al (2006) Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 47:1467–1475
Cremonesi M, Ferrari M, Di Dia A et al (2011) Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging 55:155–167
De Jong M, Valkema R, Van Gameren A et al (2004) Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med 45:1168–1171
Forrer F, Krenning EP, Kooij PP et al (2009) Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 36:1138–1146
Gabriel M, Andergassen U, Putzer D et al (2010) Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 54:92–9
Heiskanen T, Heiskanen T, Kairemo K (2009) Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Curr Pharm Des 15:988–1007
Kairemo K, Lubberink M, Garske U et al (2002) Dosimetry of repeated Y-90-octreotide therapy of somatostatin expressing tumours. World J Nucl Med 1:S134–5
Kangasmäki A, Kiljunen T, Pyyry J et al (2012) A simple individualized 3D dose calculation for radionuclide therapy—applied in 177Lu-DOTA receiving patients. (Submitted)
Konijnenberg M, Bijster M, Krenning EP et al (2004) A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with 90Y, 111In, or 177Lu. J Nucl Med 45:1260–9
Konijnenberg M, Melis M, Valkema R et al (2007) Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 48:134–142
Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog 177Lu-DOTA0, Tyr3) octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762
Lubberink M, Garske U, Sandström M et al (2002) Dosimetry of repeated Y-90-SMT 487 (Octreother) therapy of somatostatin expressing tumours using Y-90-bremsstrahlung and In-111-octreotide measurements. Eur J Nucl Med 29:S358
Melis M, Krenning EP, Bernard BF et al (2005) Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 32:1136–1143
Pauwels S, Barone R, Walrand S et al (2005) Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 46(Suppl 1):92S–8S
Seregni E, Maccauro M, Coliva A et al (2010) Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging 54:84–91
Siegel JA, Stabin MG, Sharkey RM (2010) Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm 25:581–8
Tiensuu Janson E, Sorbye H, Welin S et al (2010) Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors. Acta Oncol 49:740–756
van Eerd JE, Vegt E, Wetzels JF et al (2006) Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 47:528–533
Vegt E, Wetzels JF, Russel FG et al (2006) Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47:432–6
Wehrmann C, Senftleben S, Zachert C et al (2007) Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22:406–416
Wessels BW, Konijnenberg MW, Dale RG et al (2008) MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response–implications for radionuclide therapy. J Nucl Med 49:1884–1899
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kairemo, K., Kangasmäki, A. (2013). 4D SPECT/CT Acquisition for 3D Dose Calculation and Dose Planning in 177Lu-Peptide Receptor Radionuclide Therapy: Applications for Clinical Routine. In: Baum, R., Rösch, F. (eds) Theranostics, Gallium-68, and Other Radionuclides. Recent Results in Cancer Research, vol 194. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27994-2_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-27994-2_31
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27993-5
Online ISBN: 978-3-642-27994-2
eBook Packages: MedicineMedicine (R0)